An observational study in Kidney Stone, sponsored by Brugmann University Hospital. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Brugmann University Hospital · Observational
Neutrophils are first responders to any kind of threat the body faces: infection, severe trauma, cancer, surgery... They produce the cytokines, induct oxidative stress and de-granulate toxic proteins to kill pathogens. However the new mechanism related to the neutrophil extracellular traps release has been recognized as a new way of cell necrosis and has been called a NETosis.
NETosis is a hugely important new mechanism of human immune responses also described in various forms of acute kidney injury (ischemic, toxic, autoimmune). In certain kidney diseases, neutrophils release NETs and induce cell necrosis. Whether neutrophils die along with NET release, and if they do die, remains under study and is most likely context dependent. Extracellular traps (ETs) can be released also by macrophages. The ETs formation as well as macrophages extracellular traps (MET's) especially in kidney disease are cytotoxic and elicit inflammation, contributing to necro-inflammation of the early-injury phase of acute tubular necrosis in anti-neutrophil cytoplasmic antibody-related renal vasculitis, anti-glomerular basement membrane disease, lupus nephritis. Finally, acute kidney injury-related releases of dying renal cells or ETs promote organ injuries - for example, acute respiratory distress syndrome. According to the recent review the term 'NET formation' has been proposed as a better term to use instead of 'NETosis'. The formation of neutrophil extracellular traps (NETs) has been recently recognized as a unique modality of pathogen fixation (sticky extracellular chromatin) and pathogen killing (cytotoxic histones and proteases) during host immune responses, as well as collateral tissue damage.
Histones are potent mediators of injury in various cells. Indeed, extracellular histone induce microvascular endothelial cells and renal epithelial cells death in vitro, forms the pores that disrupt cell integrity and induce the cytolysis by their capacity of binding with membrane phospholipids and activation of inflammasome in the kidney leading to auto-entrainment of inflammation.
The activation of inflammation has been demonstrated in the experimental model of crystalline nephropathy related to the uncontrolled oxalate urinary excretion. Inhibition of inflammasome activation has been related with the preservation of kidney function. In patients with kidney stone disease the presence of crystals in the urine has been demonstrated to induce tubular epithelial cells injury that can theoretically trigger the NET's or MET's release and tissue inflammation.
NETs are now increasingly described as new targets for therapies, however largely under-estimated.
The role of release of ETs from neutrophils and macrophages during the kidney stone disease has never been studied in urine but the neutrophil extracellular trap (NET) formation-NETosis - was found significantly increased in the papillae of patients with brushite stones compared with CaOx stones.
The key objectives of this study are:
598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.
This study's planned enrollment of 500 is above the median of 144 across 110 observational studies indexed under Kidney Calculi.
Browse Kidney Calculi studies →Brugmann University Hospital is the lead sponsor of 116 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with acute and/or chronic kidney disease, with stones or without stones, ambulatory or hospitalized in CHU Brugmann Brugmann.
Exclusion Criteria:
Adult subjects with kidney stones disease
Other: Blood sampling · Other: Urine sampling
Control group: patients with acute and/or chronic kidney disease (CKD) without stones
Other: Blood sampling · Other: Urine sampling
Blood sampling
Urine sampling
Neutrophil extracellular traps (NETs) excretion in 24h urine collection
Assessment of NET excretion in 24h urine collection
Time frame: 24 hours
Neutrophil extracellular traps (NETs) excretion in fasting urine
Assessment of NET excretion in fasting urine
Time frame: 24 hours
Neutrophil extracellular traps (NETs) excretion in 2e morning urine
Assessment of NET excretion in 2e morning urine
Time frame: 24 hours
Macrophages extracellular traps (MET's) excretion in 24h urine collection
Assessment of MET's in 24h urine collection
Time frame: 24 hours
Macrophages extracellular traps (MET's) excretion in fasting urine
Assessment of MET's in fasting urine
Time frame: 24 hours
Macrophages extracellular traps (MET's) excretion in 2e morning urine
Assessment of MET's in 2e morning urine
Time frame: 24 hours
Neutrophil extracellular traps (NETs) plasma levels
Neutrophil extracellular traps (NETs) plasma levels
Time frame: 24 hours
Macrophages extracellular traps (MET's) plasma levels
Macrophages extracellular traps (MET's) plasma levels
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brugmann University Hospital